Immunovant (IMVT) Long-Term Deferred Tax (2019 - 2020)
Immunovant's (IMVT) quarterly Long-Term Deferred Tax came in at $246000.0 in Q1 2020, down 79.41% YoY from $1.2 million in Q2 2019, and up 153.61% on a QoQ basis from $97000.0 in Q3 2019.
Immunovant (IMVT) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Immunovant (IMVT) has 2 years of Long-Term Deferred Tax data on file, last reported at $246000.0 in Q1 2020.
- Quarterly Long-Term Deferred Tax fell 79.41% year-over-year to $246000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $246000.0 (down 79.41% YoY) and the FY2020 annual result came in at $246000.0, down 79.41% from the prior year.
- Long-Term Deferred Tax grew to $246000.0 in Q1 2020, from $97000.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $1.2 million in Q1 2019 to a low of $97000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 246,000.00 |
| Sep 30, 2019 | 97,000.00 |
| Mar 31, 2019 | 1.20 Mn |